x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Psychopharmacology and Psychiatry Updates

Psychopharmacology Institute

Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

health & fitness medicine

All Episodes

11:14

SSRIs and Psychedelics: Drug Interactions

Psychopharmacology and Psychiatry Updates ·

2025/10/03

In this episode, we explore the complex drug-drug interactions between psychedelics and psychiatric medications. Do SSRIs really blunt psychedelic effects, or is this just clinical folklore? We'll examine surprising new research and discuss potentially dangerous combinations every psychiatrist should know. Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Use of Psychedelic Drugs in Psychiatry Examining the Combined Use of Psychedelics and

en

14:06

Standard vs. High Doses: Rethinking Bipolar...

Psychopharmacology and Psychiatry Updates ·

2025/09/28

In this episode, we challenge the conventional wisdom of “what gets them well keeps them well” by exploring groundbreaking Finnish research on bipolar disorder medication dosing. Does maintaining patients on high doses actually improve long-term outcomes, or could standard doses be the optimal strategy for relapse prevention? Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Quick Take Vol. 73 Bipolar Disorder Maintenance: What’s the Optimal

en

14:11

Psychedelics and Brain Networks

Psychopharmacology and Psychiatry Updates ·

2025/09/23

In this episode, we explore how psychedelics like psilocybin disrupt the brain's default mode network, creating windows of neuroplasticity that correlate with mystical experiences and therapeutic breakthroughs in treatment-resistant depression, anxiety, and addiction. Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 1.25 CMEs: Use of Psychedelic Drugs in Psychiatry How Psychedelics Influence Brain Networks

en

16:33

LAIs vs Oral Antipsychotics: Mortality Data and...

Psychopharmacology and Psychiatry Updates ·

2025/09/18

In this episode, we explore groundbreaking research showing how long-acting injectable antipsychotics can literally save lives in schizophrenia treatment. Could choosing the right medication delivery method be the difference between a patient thriving or facing premature death by 15-20 years? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Quick Take Vol. 73 Long-Acting Injectables: Superior for Reducing Mortality in

en

15:55

The Science Behind Psychedelic Therapy

Psychopharmacology and Psychiatry Updates ·

2025/09/13

In this episode, we explore the fascinating mechanisms behind psychedelic drugs in psychiatry, examining how substances like psilocybin and LSD work through 5-HT2A receptors to promote neuroplasticity. What if these compounds are hijacking an ancient stress response system designed to help us rapidly adapt to survive? Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Use of Psychedelic Drugs in Psychiatry The Mechanisms and Effects of

en

12:11

Which Antidepressant Causes the Most Weight Gain?

Psychopharmacology and Psychiatry Updates ·

2025/09/08

In this episode, we explore groundbreaking research comparing weight gain across eight common antidepressants. Using data from 183,000 patients, this study finally provides concrete numbers to answer the question patients ask most: How much weight will I gain on this medication? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 72 Which Antidepressants Cause the Most Weight Gain?

en

12:14

Lisdexamfetamine for Binge Eating Disorder

Psychopharmacology and Psychiatry Updates ·

2025/09/03

In this episode, we explore lisdexamfetamine as the first FDA-approved medication for binge eating disorder. Can one medication effectively treat both ADHD and binge eating simultaneously? We examine the evidence, duration of treatment, and strategies for addressing patient ambivalence in eating disorder pharmacotherapy. Faculty: Scott Crow, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update Binge Eating Disorder

en

11:27

Beyond Weight Loss: GLP-1 Agonists and Alcohol Use...

Psychopharmacology and Psychiatry Updates ·

2025/08/29

In this episode, we explore groundbreaking Swedish research on GLP-1 receptor agonists as a potential new treatment for alcohol use disorder. Could diabetes medications like semaglutide revolutionize addiction treatment where traditional therapies have fallen short? Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 72 Which Antidepressants Cause the Most Weight Gain?

en

11:26

Antidepressants vs. Anticonvulsants for Binge Eating

Psychopharmacology and Psychiatry Updates ·

2025/08/24

In this episode, we explore pharmacotherapy for binge eating disorder, examining how antidepressants, anticonvulsants, and emerging treatments target different patient goals. Should your treatment focus on stopping binge episodes or achieving weight loss? We discuss evidence-based approaches to align medication choices with patient priorities for optimal outcomes. Faculty: Scott Crow, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating

en

11:19

Lithium Levels: Finding the Right Therapeutic Target

Psychopharmacology and Psychiatry Updates ·

2025/08/19

In this episode, we explore the confusing world of lithium therapeutic levels with Dr. Paul Zarkowski. Why do different labs recommend different ranges for the same medication? We examine expert consensus on optimal dosing strategies for both acute treatment and maintenance therapy in bipolar disorder. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 What is the Optimal Therapeutic Range for Lithium in Bipolar

en

09:28

Antidepressants Beyond Depression: Applications in...

Psychopharmacology and Psychiatry Updates ·

2025/08/14

In this episode, we explore evidence-based pharmacotherapy for bulimia nervosa, including why higher doses of SSRIs work better than standard dosing, which medications to avoid completely, and how antidepressants can be effective even without depression being present. Why does fluoxetine require 60 mg daily for optimal results? Faculty: Scott Crow M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update Bulimia Nervosa:

en

12:10

Metformin and Antipsychotic-Induced Weight Gain: An...

Psychopharmacology and Psychiatry Updates ·

2025/08/09

In this episode, we explore groundbreaking research on managing antipsychotic-induced weight gain through a comprehensive network meta-analysis. Could the combination of low-dose metformin and lifestyle modifications be the game-changer that helps patients maintain both mental stability and physical health? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 Antipsychotic-Induced Weight Gain: Best Management Strategies

en

08:17

Monthly Injections, Long-Term Recovery: Naltrexone...

Psychopharmacology and Psychiatry Updates ·

2025/08/04

In this episode, we explore extended-release naltrexone for opioid use disorder, examining its unique role as a pure antagonist in patients who require safety-sensitive careers. How do we successfully navigate the challenging initiation period when patients must be opioid-free for a week? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Examining the Efficacy of Extended-Release Naltrexone OUD

en

12:03

Antipsychotics and Aspiration Risk

Psychopharmacology and Psychiatry Updates ·

2025/07/30

In this episode, we explore the surprising link between antipsychotic medications and pneumonia risk. Did you know that pneumonia is the fourth leading cause of death in schizophrenia patients, and certain medications increase this risk in unexpected ways? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 Pneumonia in Schizophrenia: Which Antipsychotics Pose the Highest Risk for?

en

11:10

Buprenorphine, Methadone, and Naltrexone: Helping...

Psychopharmacology and Psychiatry Updates ·

2025/07/25

In this episode, we explore how to choose between methadone, buprenorphine, and naltrexone for opioid use disorder treatment. With over 100,000 overdose deaths annually, how do we match the right medication to save each patient's life? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Tailored Patient Assessment: A Key to Effective OUD Treatment

en

12:04

Managing OUD with Buprenorphine: Clinical Pearls

Psychopharmacology and Psychiatry Updates ·

2025/07/20

In this episode, we explore buprenorphine management for opioid use disorder, covering induction protocols, dosing strategies, and long-term maintenance. Why do patients need to be in withdrawal before starting this life-saving medication, and how can we make this challenging process more manageable? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Buprenorphine for Managing OUD

en

09:18

Valproate Weight Gain: Do Lower Doses Help?

Psychopharmacology and Psychiatry Updates ·

2025/07/15

In this episode, we explore groundbreaking research on valproate's dose-dependent weight gain effects. Could prescribing lower doses be the key to maintaining therapeutic benefits while minimizing one of psychiatry's most challenging side effects? Dr. Paul Zarkowski reveals surprising findings that could transform your valproate prescribing approach. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 70 Is Valproate Weight

en

09:27

Methadone for Opioid Use Disorder

Psychopharmacology and Psychiatry Updates ·

2025/07/10

In this episode, we explore methadone maintenance therapy for opioid use disorder, covering dosing strategies, recent regulatory changes, and safety considerations. Why do so many patients fail on methadone despite its proven effectiveness, and how can proper dosing make the difference between recovery and relapse? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Methadone for Managing OUD

en

13:48

Clozapine and Compulsions: New Research On An Old...

Psychopharmacology and Psychiatry Updates ·

2025/07/05

In this episode, we explore the puzzling connection between clozapine and obsessive-compulsive symptoms in schizophrenia patients. Does this wonder drug actually cause OCD, or are we missing a deeper story about how protective behaviors transform into compulsive habits? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 70 Clozapine and OCD-Like Symptoms: What's the Connection?

en

10:07

Naltrexone vs. Topiramate: FDA-Approved vs. Off-Label...

Psychopharmacology and Psychiatry Updates ·

2025/06/30

In this episode, we explore groundbreaking head-to-head research comparing topiramate and naltrexone for alcohol use disorder, revealing surprising equivalence in effectiveness. Could the off-label option actually be as good as our FDA-approved standard for treating problematic drinking? Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 69 Can Topiramate Replace FDA-Approved Medications for Alcohol Use Disorder?

en

425 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown